A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The purpose of the study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to \<5 years of age and in children at high risk of respiratory syncytial virus (RSV) disease 5 to \<18 years of age to inform the dose level selection for the next phase of development (Phase 3).
Epistemonikos ID: 0093ba78eee6d7a105f4a3b2ce4ed5e4dc9a6472
First added on: May 15, 2024